Joint with: Stromal Immunology in Health and Disease
Fibrosis: Cross Organ Pathology and Pathways to Clinical Development

Feb 02–05, 2026 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers: Florian Rieder, Tatiana Kisseleva and Marco Prunotto

  In Person
  On Demand
 Add to Calendar

Feb 02–05, 2026 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers: Florian Rieder, Tatiana Kisseleva and Marco Prunotto

Supported by the  Directors' Fund

***Meeting program subject to change.

Available Formats:   = In Person     = On Demand
Monday, February 2, 2026
Registration
4:00–8:00 PM
 Van Horne Foyer
Welcome Mixer
6:00–8:00 PM
 Van Horne Foyer
Tuesday, February 3, 2026
Breakfast
7:00–8:00 AM
 President's Hall
Welcome and Keynote Address (Joint)
8:00–9:00 AM
 Van Horne A/B
Thomas A Wynn, Pfizer
The Future of Anti-Fibrotic Therapy: Scar Macs and Beyond
From Fibroblasts to Fibrosis, and Back Again (Joint)
9:00–11:15 AM
 Van Horne A/B
Boris Hinz, St. Michael's Hospital and University of Toronto
To Push or Pull? How the Mechanical Environment Affects Stromal Activation
Sheila A. Stewart, Washington University School of Medicine
Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy
Michael B. Brenner, Harvard Medical School
Notch and Wnt Signaling in Inflammatory Fibroblast-Mediated Pathology
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
 Van Horne Foyer
Poster Setup
11:15–1:00 PM
 Van Horne C
On Own for Lunch
11:15–2:30 PM
Poster Viewing
1:00–10:00 PM
 Van Horne C
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
 Van Horne A
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
 Van Horne Foyer
Mechanisms of the Extracellular Matrix Environment Driving Disease
5:00–7:00 PM
 Van Horne A
Rachel Lennon, University of Manchester
The Matrisome in Disease Pathology
Natalie J. Torok, Stanford University
Viscoelasticity Promoting Cancer Progression
Detlef Schuppan, Beth Israel Deaconess Medical Center
Targeting the ECM to Treat Liver Fibrosis and Liver Cancer
Short Talk(s) Chosen from Abstracts
Social Hour with Dinner
7:00–8:00 PM
 President's Hall
Posters
7:30–10:00 PM
 Van Horne C
Wednesday, February 4, 2026
Breakfast
7:00–8:00 AM
 President's Hall
Fibroblast Heterogenity across Organs: A Critical Basis for Discovery and Therapy Translation
8:00–10:30 AM
 Van Horne A
Suzanne Devkota, Cedars-Sinai Medical Center
Microbiome Influence on Adipose Tissue Fibrosis
Florian Rieder, Cleveland Clinic
Fibroblast interactions in Intestinal Fibrosis
Stefanie Dimmeler, University of Frankfurt
Persistent Fibroblast Activation in the Hypertrophic Human Heart
Dean Sheppard, University of California, San Francisco
The Alveolar Fibroblast Lineage in Lung Inflammation and Fibrosis
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
 Van Horne Foyer
Panel Discussion 1: Fibroblast Heterogeneity Across Organs
10:30–11:00 AM
 Van Horne A
Poster Setup
11:00–1:00 PM
 Van Horne C
On Own for Lunch
11:00–3:30 PM
Poster Viewing
1:00–10:00 PM
 Van Horne C
Career Roundtable (Joint)
3:30–4:30 PM
 Van Horne B
Coffee Available
4:30–5:00 PM
 Van Horne Foyer
Mechanisms that Drive the Progression and Regression of Fibrosis
5:00–7:00 PM
 Van Horne A
Scott L Friedman, Icahn School of Medicine at Mount Sinai
Genetics linked with Fibrosis: Commonalities and Differences across Organs
Pilar Alcaide, Tufts University School of Medicine
The Crossroad of Inflammation and Fibrosis: Fibroblast and Immune Cell Interactions
Tatiana Kisseleva, University of California, San Diego
Mechanisms of Regression of Liver Fibrosis
Short Talk(s) Chosen from Abstracts
Social Hour with Dinner
7:00–8:00 PM
 President's Hall
Posters
7:30–10:00 PM
 Van Horne C
Thursday, February 5, 2026
Breakfast
7:00–8:00 AM
 President's Hall
Drug Development Pathways for Fibrosis – From Mechanisms to Medicine
8:00–10:30 AM
 Van Horne A
David Brenner, Sanford Burnham Prebys
Preclinical Models of Fibrosis: Are we able to Predict Therapy Response
Marco Prunotto, Medicxi
Drug Development Pathways for Fibrotic Diseases: Lessons Learned
Andrea Sáez, Agomab Therapeutics
Local Delivery ALK5 Inhibitors to Treat Lung and Intestinal Fibrosis
Shannon J Turley, Genentech, Inc.
Elucidating Regulators of Pathogenic Stroma in Fibrotic and Inflammatory Diseases
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
 Van Horne Foyer
Panel Discussion 2: Preclincial Evaluation and Clincial Development in Fibrotic Diseases
10:30–11:00 AM
 Van Horne A
On Own for Lunch
11:00–2:30 PM
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
 Van Horne A
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
 Van Horne Foyer
Therapeutic Modulation of Stromal Cell Function (Joint)
5:00–6:45 PM
 Van Horne A/B
Viviana Cremasco, Novartis Biomedical Research
TGFb Neutralization and Tumor Stroma Modulation: From Bench to Bed
Yuval Rinkevich, Helmholtz Zentrum München, GmbH
Regenerative Medicine and Tissue Repair
Burkhard Ludewig, Kantonsspital St. Gallen
Immunomodulation of Myocardial Fibrosis
Short Talk(s) Chosen from Abstracts
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (Joint)
6:45–7:00 PM
 Van Horne A/B
Social Hour with Dinner
7:00–8:00 PM
 President's Hall
Entertainment
8:00–11:00 PM
Cash Bar
8:00–11:00 PM
Friday, February 6, 2026
Departure
12:00–11:59 PM

Subscribe for Updates